Abbott Hits The Jackpot With Boston Scientific’s Acquisition Of Guidant
This article was originally published in The Gray Sheet
Executive Summary
Abbott stands poised to become a vascular and endovascular powerhouse should Boston Scientific's acquisition of Guidant clear Federal Trade Commission antitrust hurdles